Abstract:The human gut is inhabited by a multitude of bacteria, yeasts, and viruses. A dynamic balance among these microorganisms is associated with the well-being of the human being, and a large body of evidence supports a role of dysbiosis in the pathogenesis of several diseases. Given the importance of the gut microbiota in the preservation of human health, probiotics, prebiotics, synbiotics, and postbiotics have been classically used as strategies to modulate the gut microbiota and achieve beneficial effects for the host. Nonetheless, several molecules not typically included in these categories have demonstrated a role in restoring the equilibrium among the components of the gut microbiota. Among these, rifaximin, as well as other antimicrobial drugs, such as triclosan, or natural compounds (including evodiamine and polyphenols) have common pleiotropic characteristics. On one hand, they suppress the growth of dangerous bacteria while promoting beneficial bacteria in the gut microbiota. On the other hand, they contribute to the regulation of the immune response in the case of dysbiosis by directly influencing the immune system and epithelial cells or by inducing the gut bacteria to produce immune-modulatory compounds, such as short-chain fatty acids. Fecal microbiota transplantation (FMT) has also been investigated as a procedure to restore the equilibrium of the gut microbiota and has shown benefits in many diseases, including inflammatory bowel disease, chronic liver disorders, and extraintestinal autoimmune conditions. One of the most significant limits of the current techniques used to modulate the gut microbiota is the lack of tools that can precisely modulate specific members of complex microbial communities. Novel approaches, including the use of engineered probiotic bacteria or bacteriophage-based therapy, have recently appeared as promising strategies to provide targeted and tailored therapeutic modulation of the gut microbiota, but their role in clinical practice has yet to be clarified. The aim of this review is to discuss the most recently introduced innovations in the field of therapeutic microbiome modulation.

Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?

Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy

Fecal Microbiota Transplantation and Other Gut Microbiota Manipulation Strategies

Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases

Gut microbiota alteration and modulation in psychiatric disorders: Current evidence on fecal microbiota transplantation

Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation

Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models

Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns

Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators

Microbiota Transplantation: Concept, Methodology and Strategy for Its Modernization

Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook

Fecal microbiota transplantation in clinical practice: Present controversies and future prospects

Microbiota Therapy in Inflammatory Bowel Disease

Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome

An Ecological Framework to Understand the Efficacy of Fecal Microbiota Transplantation

Fecal microbiota transplantation: in perspective

Modulation of Gut Microbiota in Pathological States

Impacts of Gut Microbiota on the Immune System and Fecal Microbiota Transplantation as a Re-Emerging Therapy for Autoimmune Diseases

An update on clinical practice of fecal microbiota transplantation

Fecal microbiota transplantation: current challenges and future landscapes

Fecal Microbiota Transplantation: A Potential Tool for Treatment of Human Female Reproductive Tract Diseases